Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China

Table 2 Primary data retrieved from literatures

Regimens studies	N	CR+PR		MST	DMC
		n	%	(mo)	(￥, RMB)
5FU+ADM/EPI+MMC (FAM)
Dong[5]	16	7	43.8	6.0	2439.78
Yu[6]	15	6	40.0	13.5	1965.00
Ding[7]	18	7	38.9	11.5	1888.50
Qian[8]	35	12	34.3	11.5	1509.78
DDP+VP-16+ADM/EPI (EAP)
Dong[5]	13	7	53.8	8.0	2952.42
Yu[6]	12	6	50.0	9.0	2705.00
Ding[7]	15	8	53.3	8.5	2170.00
5FU+VP-16+CF (ELF)
Dong[5]	15	7	46.7	9.0	3823.05
Yu[6]	14	8	57.1	13.0	1640.00
Ding[7]	1	9	56.3	13.0	1602.00
UFT+MMC (UFTM)
Qian[8]	49	16	32.6	8.5	2322.80
UFT+DDP+VP-16 (FEP)
Qian[8]	51	24	47.9	10.0	1902.90
5FU+CF+DDP+MMC (LFP/M)
Qian[8]	91	40	44.0	9.0	2907.76
5FU+CF+ADM+MTX (FAMTX)
Yang[9]	UR	UR	21.0	6.1	1705.28
5FU+EPI+DDP (ECF)
Yang[9]	UR	UR	46.0	8.7	1526.67
Liu[11]	30	12	40.0	UR	4158.00
5FU+DDP+PTX (TCF)
Zhou[10]	22	11	50.0	UR	2640.60
5FU+CF+DXL+DDP (DCF)
Liu[11]	32	18	56.3	UR	9979.00
5FU+CF+L-OHP (FOLFOX)
Zhou[10]	26	12	46.1	UR	1588.99
Liu[11]	34	18	52.9	UR	4498.00

CR: Complete response; PR: Partial response; MST: Median survival time; DMC: Per capita direct medical cost of single cycle; 5FU: 5-fluorouracil; ADM: Adriamycin; EPI: Epirubicin; MMC: Mitomycin; DDP: Cisplatin; VP-16: Etoposide; CF: Calcium Leucovorin; UFT: Uracil-tegafur; MTX: Methotrexate; PTX: Paclitaxel; DXL: Docetaxel; L-OHP: Oxaliplatin; UR: Unretrieved data.